Bridging Pharma

Bridging Pharma is a specialty pharmaceutical company focused on the development and commercialization of value-added medicines through the FDA's 505(b)(2) regulatory pathway. The company specializes in reformulating existing, approved drug products to enhance their therapeutic profile, improve patient compliance, and address unmet medical needs. Their current pipeline targets significant opportunities in pain management, central nervous system (CNS) disorders, and oncology support. By leveraging established clinical data, Bridging Pharma aims to reduce development risks and timelines while delivering differentiated treatments to the market. The company operates with a capital-efficient model, focusing on strategic asset selection and innovative drug delivery technologies.